Quest for the right Drug

|
עמוד הבית / אזופט %1 / מידע מעלון לרופא

אזופט %1 AZOPT 1% (BRINZOLAMIDE)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

עיני : OCULAR

צורת מינון:

תרחיף לעין : OPHTHALMIC SUSPENSION

Posology : מינונים

4.2     Posology and method of administration
Posology

When used as monotherapy or adjunctive therapy, the dose is one drop of Azopt 1% in the conjunctival sac of the affected eye(s) twice daily. Some patients may have a better response with one drop three times a day.

Special populations

Elderly population
No dose adjustment in elderly patients is necessary.
Hepatic and renal impairment
Azopt 1% has not been studied in patients with hepatic impairment and is therefore not recommended in such patients.
Azopt 1% has not been studied in patients with severe renal impairment (creatinine clearance ˂ 30 ml/min) or in 
patients with hyperchloraemic acidosis. Since brinzolamide and its main metabolite are excreted predominantly by the kidney, Azopt 1% is therefore contra-indicated in such patients (see also section 4.3).

Paediatric population
The safety and efficacy of Azopt 1% in infants, children and adolescents aged 0 to 17 years have not been established. Currently available data are described in sections 4.8 and 5.1. Azopt 1% is not recommended for use in infants, children and adolescents.

Method of administration

For ocular use.
Nasolacrimal occlusion or gently closing the eyelid after instillation is recommended. This may reduce the systemic absorption of medicinal products administered via the ocular route and result in a decrease in systemic side effects.

Instruct the patient to shake the bottle well before use. After the cap is removed, if tamper evident snap collar is loose, remove before using the product.

To prevent contamination of the dropper tip and suspension, care must be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle. Instruct patients to keep the bottle tightly closed when not in use.

When substituting another ophthalmic antiglaucoma agent with Azopt 1% , discontinue the other agent and start the following day with Azopt 1% .

If more than one topical ophthalmic medicinal product is being used, the medicines must be administered at least 5 minutes apart. Eye ointments should be administered last.

If a dose is missed, treatment should be continued with the next dose as planned. The dose should not exceed one drop in the affected eye(s) three times daily.

שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל 01/04/2004
הגבלות תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת

בעל רישום

NOVARTIS ISRAEL LTD

רישום

136 60 29640 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

25.08.22 - עלון לרופא

עלון מידע לצרכן

10.05.18 - עלון לצרכן 19.12.21 - עלון לצרכן אנגלית 25.08.22 - עלון לצרכן עברית 19.12.21 - עלון לצרכן ערבית 10.10.22 - עלון לצרכן אנגלית 10.10.22 - עלון לצרכן עברית 10.10.22 - עלון לצרכן ערבית 13.12.15 - החמרה לעלון 25.08.22 - החמרה לעלון

לתרופה במאגר משרד הבריאות

אזופט %1

קישורים נוספים

RxList WebMD Drugs.com